Livanova Plc OR Sh (LIVN) Stock Price, Quote & News

Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy...

Industry: Medical Devices

Sector: Healthcare

Phone: 44 20 3325 0660

Website: www.livanova.com

Address:

20 Eastbourne Terrace, London, United Kingdom

WayneSmith Nov. 14 at 7:45 PM

$JD $LIVN A steady stream of buying is pushing the market higher and higher.

0 · Reply

THE_Perfusionist Nov. 14 at 2:34 AM

For those in the back…these companies like $MDT and $LIVN are rocking the ECMO world. $IINN not so much.

0 · Reply

armandleighton Nov. 13 at 11:31 PM

$JD $LIVN The market is embarking on a short-squeeze rally. https://stocktwits.com/armandleighton

0 · Reply

erevnon Nov. 13 at 1:03 PM

Baird maintains LivaNova $LIVN at Outperform and raises the price target from $63 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Nov. 13 at 12:38 PM

Mizuho has adjusted their stance on LivaNova ( $LIVN ), setting the rating to Outperform with a target price of 65 → 70.

0 · Reply

JarvisFlow Nov. 13 at 12:37 PM

Baird has updated their rating for LivaNova ( $LIVN ) to Outperform with a price target of 70.

0 · Reply

SuperGreenToday Nov. 12 at 10:06 PM

$LIVN Share Price: $56.65 Contract Selected: Apr 17, 2026 $57.5 Calls Buy Zone: $1.40 – $1.73 Target Zone: $2.23 – $2.73 Potential Upside: 50% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

notreload_ai Nov. 12 at 8:49 PM

$LIVN outlines a strong 2030 roadmap with targets for high revenue growth, expanded margins, and new innovations in Epilepsy, Cardiopulmonary, and Sleep Apnea treatments. https://notreload.xyz/livanova-sets-2030-growth-goals-expands-innovation/

0 · Reply

JarvisFlow Nov. 6 at 5:36 PM

Baird has updated their rating for LivaNova ( $LIVN ) to Outperform with a price target of 63.

0 · Reply

Estimize Nov. 5 at 11:09 PM

$LIVN reported 1.11 EPS and 357.80 revenue for Q3. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm

0 · Reply

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

Nov 5, 2025, 3:41 PM EST - 9 days ago

LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 6:00 AM EST - 9 days ago

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

Oct 23, 2025, 9:00 AM EDT - 22 days ago

LivaNova to Present at Wolfe Research Healthcare Conference in November

Oct 22, 2025, 11:50 PM EDT - 22 days ago

LivaNova: Robust Fundamentals, Long-Term Growth Potential

Oct 8, 2025, 9:00 AM EDT - 5 weeks ago

LivaNova to Announce Third-Quarter 2025 Results

Oct 7, 2025, 9:00 AM EDT - 5 weeks ago

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

Sep 10, 2025, 4:00 PM EDT - 2 months ago

LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 9:00 AM EDT - 2 months ago

LivaNova Appoints Donald Zurbay as a New Director

Aug 25, 2025, 9:00 AM EDT - 2 months ago

LivaNova to Host Investor Day on November 12, 2025

Aug 22, 2025, 9:00 AM EDT - 3 months ago

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

Aug 18, 2025, 9:00 AM EDT - 3 months ago

LivaNova Launches Essenz Perfusion System in China

Aug 6, 2025, 11:18 PM EDT - 3 months ago

LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 6:00 AM EDT - 3 months ago

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

Jul 9, 2025, 9:00 AM EDT - 4 months ago

LivaNova to Announce Second-Quarter 2025 Results

Jul 7, 2025, 1:34 PM EDT - 4 months ago

LivaNova: The Sell-Off Is Excessive Here

Jun 5, 2025, 8:15 AM EDT - 5 months ago

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Jun 5, 2025, 8:00 AM EDT - 5 months ago

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Jun 4, 2025, 8:00 AM EDT - 5 months ago

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

May 15, 2025, 8:00 AM EDT - 6 months ago

LivaNova to Present at the Jefferies Global Healthcare Conference

May 11, 2025, 2:56 AM EDT - 6 months ago

LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

May 7, 2025, 6:00 AM EDT - 6 months ago

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

May 7, 2025, 5:45 AM EDT - 6 months ago

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

Mar 26, 2025, 8:00 AM EDT - 8 months ago

LivaNova to Announce First-Quarter 2025 Results

Feb 25, 2025, 7:10 PM EST - 9 months ago

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 6:00 AM EST - 9 months ago

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

Feb 21, 2025, 9:00 AM EST - 9 months ago

LivaNova to Present at the Barclays Global Healthcare Conference

Jan 21, 2025, 9:00 AM EST - 10 months ago

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Dec 18, 2024, 8:30 AM EST - 11 months ago

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Dec 5, 2024, 9:00 AM EST - 1 year ago

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

Nov 14, 2024, 9:00 AM EST - 1 year ago

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

Nov 11, 2024, 4:05 PM EST - 1 year ago

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Oct 30, 2024, 2:30 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports Third-Quarter 2024 Results

Oct 18, 2024, 3:45 AM EDT - 1 year ago

LivaNova: Economics Should Start Making Sustained Improvements

Oct 8, 2024, 9:00 AM EDT - 1 year ago

LivaNova Appoints Susan Podlogar as a New Director

Oct 4, 2024, 11:59 AM EDT - 1 year ago

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

Sep 25, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce Third-Quarter 2024 Results

Aug 19, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Baird Global Healthcare Conference

Jul 31, 2024, 1:57 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports Second-Quarter 2024 Results

Jun 24, 2024, 6:24 PM EDT - 1 year ago

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

Jun 18, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce Second-Quarter 2024 Results

Jun 6, 2024, 9:00 AM EDT - 1 year ago

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

May 23, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Goldman Sachs Healthcare Conference

May 1, 2024, 10:56 AM EDT - 1 year ago

LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript

May 1, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports First-Quarter 2024 Results

Apr 30, 2024, 9:00 AM EDT - 1 year ago

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

WayneSmith Nov. 14 at 7:45 PM

$JD $LIVN A steady stream of buying is pushing the market higher and higher.

0 · Reply

THE_Perfusionist Nov. 14 at 2:34 AM

For those in the back…these companies like $MDT and $LIVN are rocking the ECMO world. $IINN not so much.

0 · Reply

armandleighton Nov. 13 at 11:31 PM

$JD $LIVN The market is embarking on a short-squeeze rally. https://stocktwits.com/armandleighton

0 · Reply

erevnon Nov. 13 at 1:03 PM

Baird maintains LivaNova $LIVN at Outperform and raises the price target from $63 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Nov. 13 at 12:38 PM

Mizuho has adjusted their stance on LivaNova ( $LIVN ), setting the rating to Outperform with a target price of 65 → 70.

0 · Reply

JarvisFlow Nov. 13 at 12:37 PM

Baird has updated their rating for LivaNova ( $LIVN ) to Outperform with a price target of 70.

0 · Reply

SuperGreenToday Nov. 12 at 10:06 PM

0 · Reply

notreload_ai Nov. 12 at 8:49 PM

0 · Reply

JarvisFlow Nov. 6 at 5:36 PM

Baird has updated their rating for LivaNova ( $LIVN ) to Outperform with a price target of 63.

0 · Reply

Estimize Nov. 5 at 11:09 PM

$LIVN reported 1.11 EPS and 357.80 revenue for Q3. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm

0 · Reply

Mogeyman Nov. 5 at 3:42 PM

$LIVN

0 · Reply

JackDarwin Nov. 5 at 12:53 PM

$LIVN Bullish Engulfing Candlestick Pattern

0 · Reply

Mogeyman Nov. 4 at 4:55 PM

$LIVN

0 · Reply

Estimize Nov. 3 at 11:03 AM

Wall St is expecting 0.92 EPS for $LIVN Q3 [Reporting 11/05 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co

0 · Reply

Mogeyman Sep. 23 at 12:06 PM

$LIVN

0 · Reply

healthcareguru Sep. 16 at 7:35 PM

$LIVN back to $50 👎

0 · Reply

THE_Perfusionist Sep. 12 at 9:36 PM

$IINN $LIVN has them beat along with other Huge player like $MDT https://www.livanova.com/cardiopulmonary/en-us/essenz/in-line-blood-monitor https://www.medtronic.com/en-us/healthcare-professionals/products/cardiovascular/extracorporeal-membrane-oxygenation/nautilus-smart-ecmo-oxygenator-module.html This disposable ECMO oxy has this tech built in! This is where the ECMO space is going. Not standalone devices.

3 · Reply

Mogeyman Sep. 9 at 7:56 PM

$LIVN

0 · Reply

JarvisFlow Sep. 3 at 12:00 PM

Needham has updated their rating for LivaNova ( $LIVN ) to Buy with a price target of 64.

0 · Reply

Mogeyman Sep. 3 at 10:44 AM

$LIVN

0 · Reply

Mogeyman Aug. 28 at 11:34 AM

$LIVN

0 · Reply

healthcareguru Aug. 27 at 12:19 AM

$LIVN

0 · Reply

Market Cap	3.09B
Revenue (ttm)	1.25B
Net Income (ttm)	63.23M
EPS (ttm)	N/A
PE Ratio	15.54
Forward PE	16.23
Profit Margin	5.04%
Debt to Equity Ratio	0.38

Volume	595,685
Avg Vol	551,992
Day's Range	N/A - N/A
Shares Out	54.61M
Stochastic %K	71%
Beta	1.00
Analysts	Strong Sell
Price Target	$67.89